On Monday, a Delaware federal jury awarded $155 million to Bayer for infringement of U.S. Patent No. 9,364,520, which covers several of Bayer’s hemophilia medications, including Kogenate, Kogenate FS, and Kovaltry. The ‘520 patent claims full-length Factor VIII that is pegylated at its B-domain site and compositions thereof. The verdict was entered…
